Viewing nowGenewon Olmesartan Tablet 40mg (Olmesartan Medoxomil)
Olmesartan Medoxomil 40mg
Tablet · Prescription medication
Genewon Science Co., Ltd.

MFDS item code 201400393 · Approved 2014.01.28 · Insurance code 671704150
Treatment of essential hypertension
Essential hypertension is a condition where blood pressure is consistently high, increasing the risk of cardiovascular diseases. This medicine effectively lowers blood pressure in patients with essential hypertension, reducing the burden on the heart and blood vessels. Consistent treatment helps to decrease the risk of complications and to maintain healthy blood pressure levels. Additionally, using it in conjunction with lifestyle modifications can enhance treatment effects. It is used for the treatment of essential hypertension.
<Adults> The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase the dose to 20mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40mg daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum after approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered in combination with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time every day (e.g., in the morning), if possible. For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. <Elderly patients> No dose adjustment is required when administering this medicine to patients aged 65 years or older. No overall differences in the efficacy or safety of this medicine were observed between elderly and younger patients; however, the possibility of a more sensitive response in some elderly patients cannot be ruled out. <Patients with renal impairment> The maximum dose for patients with mild to moderate renal impairment (creatinine clearance 20-60mL/min) is 20mg once daily. <Patients with hepatic impairment> No dose adjustment is required for patients with mild hepatic impairment. For patients with moderate hepatic impairment, the recommended initial dose is 10mg once daily, and the dose may be increased to a maximum of 20mg daily. As there is no experience with use in patients with severe hepatic impairment, administration of this medicine is not recommended.
<Pediatric> The safety and efficacy in children have not been established.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be stopped immediately upon confirmation of pregnancy. Individuals with allergies to this drug or its ingredients, pregnant or breastfeeding women, patients undergoing kidney dialysis, those with severe liver dysfunction, and patients with biliary obstruction should not take this drug. Patients with certain genetic disorders, such as lactose intolerance, should also avoid taking this drug. Those with low blood volume or salt may experience low blood pressure; therefore, they should consult their healthcare provider and monitor their condition closely. Caution is necessary for patients with severe heart failure or kidney function abnormalities as there is a risk of worsening kidney function. Patients with reduced kidney function should have regular blood tests to monitor potassium and creatinine levels. Patients with renal artery stenosis should also exercise caution as kidney function may worsen when taking this medication. There is a risk of hyperkalemia; therefore, especially patients with heart failure or kidney disorders should frequently check their serum potassium levels. Patients with aortic or mitral valve stenosis and hypertrophic obstructive cardiomyopathy should be cautious when using this medication. Patients with primary hyperaldosteronism are not recommended to take this drug due to inadequate response. Dizziness may occur during treatment, so driving or engaging in hazardous activities should be avoided. This medication may have a somewhat lesser blood pressure-lowering effect in Black patients. Although this drug is generally safe, side effects such as dizziness, headaches, back pain, dyspepsia, chest pain, peripheral edema, etc. can rarely occur. Abnormal reactions such as liver dysfunction or vascular edema, or increased blood pressure have also been reported. If abnormal symptoms occur, immediate consultation with a healthcare provider is necessary. If chronic diarrhea or significant weight loss occurs while taking this medication, chronic malabsorption syndrome should be suspected, prompting consultation with a doctor. Drug interactions may occur when taking other antihypertensive medications, potassium-sparing diuretics, lithium, and non-steroidal anti-inflammatory analgesics, so patients must inform their healthcare provider about all medications they are taking. Particularly, diabetic patients or those with reduced kidney function should avoid combining with aliskiren; if combined, blood pressure and kidney function should be monitored closely. Pregnant women should avoid this medication due to the serious risks to the fetus, and breastfeeding women should consider stopping the medication or breastfeeding due to potential effects on the infant. Safety in pediatrics has not been established, so use in children should be approached with caution. Elderly patients may require dose adjustments due to potential increases in drug concentration in the body. In cases of overdose, symptoms like hypotension, palpitations, and bradycardia may occur, and immediate treatment should be sought.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is important to maintain a storage temperature between 1 and 25 degrees Celsius to preserve the medication's effectiveness and safety.
White, oblong film-coated tablets
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowOlmesartan Medoxomil 40mg
Tablet · Prescription medication
Genewon Science Co., Ltd.

Olmesartan Medoxomil 10mg
Tablet · Prescription medication
JW Pharmaceutical Corporation

Olmesartan Medoxomil 40mg
Tablet · Prescription medication
JW Pharmaceutical Corp.

Olmesartan Medoxomil 20mg
Tablet · Prescription medication
JW Pharmaceutical Corporation

Olmesartan Medoxomil 20mg
Tablet · Prescription medication
Dongkuk Pharmaceutical Co., Ltd.

Olmesartan Medoxomil 10mg
Tablet · Prescription medication
DongKook Pharmaceutical Co., Ltd.

Olmesartan Medoxomil 20mg
Tablet · Prescription medication
Hana Pharmaceutical Co., Ltd.

Olmesartan Medoxomil 20mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.